triiodothyronine has been researched along with Hyperlipidemias in 26 studies
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.
Hyperlipidemias: Conditions with excess LIPIDS in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Low-T3 syndrome is a strong predictor of death in cardiac patients and might be directly implicated in the poor prognosis of cardiac patients." | 2.71 | Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. ( Donato, L; Iervasi, G; L'Abbate, A; Landi, P; Pingitore, A; Raciti, M; Ripoli, A; Scarlattini, M, 2003) |
| "Hypothyroidism has been linked with low grade inflammation, elevated risk of hepatic steatosis and atherosclerosis." | 1.40 | Thyroid hormone status regulates the expression of secretory phospholipases. ( Boilard, E; Levesque, T; Park, EA; Sharma, P, 2014) |
| "Hyperlipidemia is a secondary disorder associated with many metabolic disorders including hypothyroidism." | 1.32 | The secondary dyslipidemia and deranged serum phosphate concentration in thyroid disorders. ( Abdel-Gayoum, AA; Al-Tonsi, AA; Saad, M, 2004) |
| "The biguanides were a therapeutic enrichment particularly in the treatment of adipose elderly diabetics with obligatory diet." | 1.26 | [Indications and results of an additional differentiated pharmacotherapy of obesity]. ( Kucher, E, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (69.23) | 18.7374 |
| 1990's | 1 (3.85) | 18.2507 |
| 2000's | 3 (11.54) | 29.6817 |
| 2010's | 4 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sharma, P | 1 |
| Levesque, T | 1 |
| Boilard, E | 1 |
| Park, EA | 1 |
| Domouzoglou, EM | 1 |
| Fisher, FM | 1 |
| Astapova, I | 1 |
| Fox, EC | 1 |
| Kharitonenkov, A | 1 |
| Flier, JS | 1 |
| Hollenberg, AN | 1 |
| Maratos-Flier, E | 1 |
| Yang, N | 1 |
| Zhang, DL | 1 |
| Hao, JY | 1 |
| Wang, G | 1 |
| Selvaraj, S | 1 |
| Klein, I | 1 |
| Danzi, S | 1 |
| Akhter, N | 1 |
| Bonow, RO | 1 |
| Shah, SJ | 1 |
| Iervasi, G | 1 |
| Pingitore, A | 1 |
| Landi, P | 1 |
| Raciti, M | 1 |
| Ripoli, A | 1 |
| Scarlattini, M | 1 |
| L'Abbate, A | 1 |
| Donato, L | 1 |
| FELDMAN, EB | 1 |
| CARTER, AC | 1 |
| SCHWARZ, G | 2 |
| HUHNSTOCK, K | 2 |
| MECIANI, L | 1 |
| BRINA, A | 1 |
| RUEGAMER, WR | 1 |
| HOLTEN, C | 1 |
| Al-Tonsi, AA | 1 |
| Abdel-Gayoum, AA | 1 |
| Saad, M | 1 |
| Savoie, JC | 1 |
| Thomas, G | 1 |
| Gayno, JP | 1 |
| Laurent, MF | 1 |
| Savoie, F | 1 |
| Leger, AF | 1 |
| Shakir, KM | 1 |
| Kroll, S | 1 |
| Aprill, BS | 1 |
| Drake, AJ | 1 |
| Eisold, JF | 1 |
| Liberopoulos, E | 1 |
| Miltiadous, G | 1 |
| Elisaf, M | 1 |
| Halawa, B | 1 |
| Mazurek, W | 1 |
| Leffert, HL | 1 |
| Weinstein, DB | 1 |
| Spanio, P | 1 |
| Kucher, E | 1 |
| Jackson, P | 1 |
| Lees, S | 1 |
| Pow, M | 1 |
| Willing, GW | 1 |
| Watson, D | 1 |
| Wilke, H | 1 |
| Hagemann, J | 1 |
| Regler, B | 1 |
| Frahm, H | 1 |
| Schmidt, FJ | 1 |
| Gless, KH | 1 |
| Oster, P | 1 |
| Hüfner, M | 1 |
| LaFranchi, S | 1 |
| Hanna, CE | 1 |
| Illingworth, DR | 1 |
| Kriukova, IV | 1 |
| Kandror, VI | 1 |
| Meuret, G | 1 |
| Hoffmann, G | 1 |
| Fasel, A | 1 |
2 trials available for triiodothyronine and Hyperlipidemias
| Article | Year |
|---|---|
Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease.
Topics: Aged; Female; Follow-Up Studies; Heart Diseases; Humans; Hyperlipidemias; Logistic Models; Male; Mid | 2003 |
Nicotinic acid decreases serum thyroid hormone levels while maintaining a euthyroid state.
Topics: Adult; Female; Humans; Hyperlipidemias; Liver; Liver Function Tests; Male; Middle Aged; Niacin; Thyr | 1995 |
24 other studies available for triiodothyronine and Hyperlipidemias
| Article | Year |
|---|---|
Thyroid hormone status regulates the expression of secretory phospholipases.
Topics: Anilides; Animals; Gene Expression Regulation, Enzymologic; Group II Phospholipases A2; Hep G2 Cells | 2014 |
Fibroblast growth factor 21 and thyroid hormone show mutual regulatory dependency but have independent actions in vivo.
Topics: Adipose Tissue, Brown; Animals; Energy Metabolism; Female; Fibroblast Growth Factors; Gene Expressio | 2014 |
Serum levels of thyroid hormones and thyroid stimulating hormone in patients with biliogenic and hyperlipidaemic acute pancreatitis: Difference and value in predicting disease severity.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Bile Ducts; Biomarkers; Female; Humans; Hyperlipidemi | 2016 |
Association of serum triiodothyronine with B-type natriuretic peptide and severe left ventricular diastolic dysfunction in heart failure with preserved ejection fraction.
Topics: Age Factors; Aged; Blood Pressure; Diabetes Mellitus; Diastole; Echocardiography; Female; Heart Fail | 2012 |
REDUCTION OF SERUM TRIGLYCERIDES IN PATIENTS TREATED WITH SODIUM D-THYROXINE.
Topics: Blood Chemical Analysis; Child; Dextrothyroxine; Glycerides; Hypercholesterolemia; Hyperlipidemias; | 1963 |
[THE TREATMENT OF HYPERLIPEMIAS AND HYPERCHOLESTEREMIAS WITH D-TRIIODOTHYRONINE].
Topics: Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type III; T | 1964 |
[POSSIBILITIES AND LIMITATIONS OF THE AMBULATORY TREATMENT OF DISLIPIDEMIA IN CORONARY DISEASE PATIENTS WITH TRIAC (TRIIODOTHYROACETIC ACID). II.USE OF TRIAC ASSOCIATED WITH VITAMIN A AND DIVANILLIDENE-CYCLOHEXANONE (D.V.C.E.)].
Topics: Aged; Cholesterol; Coronary Disease; Cyclohexanones; Drug Therapy; Humans; Hyperlipidemias; Lipids; | 1964 |
3,5 DIIODOTHYROACETIC ACID MOBILIZATION OF RAT LIVER LIPID AND RELATIVE TOXICITY OF ORAL TRIAC AND TRIPROP.
Topics: Acetates; Bile Acids and Salts; Cholesterol; Dietary Fats; Diiodothyronines; Hyperlipidemias; Lipid | 1965 |
[D-TRIIODOTHYRONINE TREATMENT OF ESSENTIAL HYPERLIPEMIA AND HYPERCHOLESTEREMIA].
Topics: Drug Therapy; Hypercholesterolemia; Hyperlipidemias; Triiodothyronine | 1964 |
[D-TRIIODOTHYRONINE IN THE TREATMENT OF FAT METABOLISM DISORDERS].
Topics: Drug Therapy; Humans; Hyperlipidemias; Lipid Metabolism Disorders; Triiodothyronine | 1964 |
The secondary dyslipidemia and deranged serum phosphate concentration in thyroid disorders.
Topics: Cholesterol; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hyperlipidemias; Middle Aged; Phosph | 2004 |
[Unusual concentrations of triiodothyronine in the serum due to anti-T3 autoantibodies].
Topics: Adult; Autoantibodies; Female; Graves Disease; Humans; Hyperlipidemias; Male; Middle Aged; Triiodoth | 1982 |
Impressive lipid changes following hypolipidaemic drug administration can unveil subclinical hyperthyroidism.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Fibric Acids; Humans; Hyperlipidemias; Hyperthyr | 2001 |
[Serum levels of thyrotropin triiodothyronine, thyroxine and thyroxine-binding proteins in patients with coronary disease and hyperlipoproteinemia of the IIA and IIB types].
Topics: Coronary Disease; Humans; Hyperlipidemias; Middle Aged; Thyrotropin; Thyroxine; Thyroxine-Binding Pr | 1979 |
Growth control of differentiated fetal rat hepatocytes in primary monolayer culture. IX. Specific inhibition of DNA synthesis initiation by very low density lipoprotein and possible significance to the problem of liver regeneration.
Topics: Amino Acids; Animals; Arginine; Blood Proteins; Cell Division; Cells, Cultured; DNA; Glucagon; Hepar | 1976 |
[Obesity and pregnancy].
Topics: Adult; Blood; Cholesterol; Female; Humans; Hyperlipidemias; Insulin; Lipoproteins, LDL; Obesity; Pre | 1976 |
[Indications and results of an additional differentiated pharmacotherapy of obesity].
Topics: Adolescent; Adult; Aged; Biguanides; Diabetes Mellitus; Diet, Reducing; Female; Furosemide; Humans; | 1978 |
Radioimmunoassay kits for thyroid hormones.
Topics: Blood Proteins; Costs and Cost Analysis; Female; Humans; Hyperlipidemias; Hypothyroidism; Pregnancy; | 1976 |
[Modification of various parameters of fat metabolism and the hypophyseal-hypothalamic regulation through therapeutic doses of d-triiodothyronine].
Topics: Humans; Hyperlipidemias; Hypothalamo-Hypophyseal System; Lipids; Triiodothyronine | 1976 |
[TSH-secretion, thyroxine- and triiodothyronine concentrations under D-thyroxine administration].
Topics: Humans; Hyperlipidemias; Hypothyroidism; Thyrotropin; Thyroxine; Triiodothyronine | 1976 |
Effect of growth hormone replacement on development of hypothyroidism and hyperlipidemia.
Topics: Adolescent; Child; Child, Preschool; Cholesterol; Creatine Kinase; Female; Growth; Growth Hormone; H | 1985 |
[Method of prevention of increase in the concentration of free fatty acids in the serum of rabbits].
Topics: Animals; Fatty Acids, Nonesterified; Heparin; Hyperlipidemias; Nicotinic Acids; Rabbits; Starvation; | 1974 |
[Studies on the interpretation of the triiodothyronine test].
Topics: Blood Proteins; Chemistry, Clinical; Humans; Hyperlipidemias; Iodine Radioisotopes; Protein Binding; | 1968 |
[Thromboembolism prevention with triiodothyronine].
Topics: Humans; Hyperlipidemias; Postoperative Complications; Thromboembolism; Triiodothyronine | 1969 |